PRT064445

01/01/2023 - "In this study, we aim to describe the rate of acute hemostasis and thromboembolic complications with andexanet for refractory pericardial bleeding during AF ablation. "
01/01/2023 - "Next, the reversal effect of andexanet alfa on the anticoagulation activity and the hemostasis were demonstrated in patients with acute major bleeding while on FXa inhibitor treatment in the global phase 3b/4 study (ANNEXA-4 study). "
01/01/2023 - "In nonclinical studies, andexanet alfa significantly inhibited bleeding induced by FXa inhibitors in animal bleeding models. "
01/01/2022 - "Clinical studies of andexanet alfa and PCC for the management of DXI-associated life-threatening bleeding require further investigation in the pediatric population."
12/01/2021 - "In this study, we analyzed the efficacy and safety of patients treated with andexanet alfa for bleeding events from DOAC. "

08/01/2022 - "Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series."
10/01/2023 - "The case series investigates clinical outcomes of four patients receiving concomitant Andexanet alfa and Four Factor Prothrombin Concentrate Complex (4 F-PCC) for acute reversal of intracranial hemorrhage. "
10/01/2023 - "Concomitant andexanet alfa and 4 F-PCC for Factor Xa inhibitor associated intracranial hemorrhage."
01/01/2023 - "Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage."
01/01/2023 - "The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage."

08/01/2023 - "Case Report: Extended Duration Andexanet Alfa Infusion in a Surgical Trauma Patient."
08/01/2019 - "After trauma, animals were randomised 1:1:1 to a single andexanet bolus (1000 mg), a bolus (1000 mg) plus infusion (1200 mg over 2 h), or vehicle (control). "
08/01/2019 - "Haemodynamic parameters and markers of shock recovered to pre-trauma levels in andexanet-treated animals. "
08/06/2021 - "Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients."
08/01/2019 - "Andexanet effectively reversed apixaban anticoagulation and reduced blood loss induced by severe trauma. "

08/21/2023 - " The aim of this study was to assess the dose-related effectiveness of andexanet in reducing blood loss, improving survival, and reversing apixaban anticoagulation in a porcine polytrauma model. "
08/01/2019 - "This study evaluated andexanet for reversing apixaban anticoagulation in a porcine polytrauma model. "
08/21/2023 - "Dose-Related Effectiveness of Andexanet Alfa for Reversal of Apixaban Anticoagulation in a Porcine Polytrauma Model."
08/21/2023 - " In a porcine polytrauma model with major bleeding on apixaban, andexanet dose dependently decreased anti-FXa activity. "

09/01/2023 - "Methods: We conducted a multicenter, chart review of 100 consecutive adult patients with FXa-I associated intracerebral hemorrhage (50) or gastrointestinal bleeding (50) treated with andexanet alfa or 4F-PCC. "
01/01/2023 - "Comment on "Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa"."
01/01/2023 - "Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa."
11/23/2021 - "Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage."
11/23/2021 - "Andexanet Alfa for Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: Does a Specific Reversal Agent Justify Its Cost?"